Status: Recruiting
BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
The goal of this clinical trial is to test BSB-1001 which is a new type of cellular therapy to treat blood cancers (AML, ALL and MDS). It will evaluate the safety of BSB-1001 and also determine whether it works to prevent relapse of your cancer.
Participants needed: 38
Trial details
Phase: Phase 1, Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: BlueSphere Bio, IncUpdated: Sep 18, 2025Locations: 6
Eligibility criteria
Male or female patients, ages 18 - 70 years inclusive, undergoing alloHCT. [+7]
Weight > 100 kg. [+10]